Technology ID
TAB-4595

Antibodies to TMC1 Protein for Hearing Loss

E-Numbers
E-160-2016-0
Lead Inventor
Griffith, Andrew (NIDCD)
Co-Inventors
Makishima, Tomoko (University of Texas Medical Branch)
Labay, Valentina (Otsuka Maryland Medicinal Laboratories, Inc)
Applications
Therapeutics
Research Materials
Development Stages
Pre-Clinical (in vitro)
Research Products
Antibodies
Lead IC
NIDCD
ICs
NIDCD

This technology includes antibodies for TMC1 protein as a treatment for hearing loss. TMC1 is one of the common genes causing hereditary hearing loss. Our laboratory used synthetic peptides corresponding to the TMC1 protein to immunize rabbits. The resulting antisera were shown to bind to TMC1 protein expressed in heterologous expression systems. TMC1 protein is required for the transduction of sound into electrical impulses in inner ear sensory cells.

Commercial Applications
  • Future treatment for hearing loss.
Competitive Advantages
  • Antibodies that specifically bind TMC1 protein are difficult to make; there are commercially available antibodies to TMC1 but they do not appear to be as sensitive or specific or as carefully characterized as the antibodies generated in this invention.

Request More Info

Licensing Contact:
Shmilovich, Michael
shmilovm@nih.gov

Publications

Collaborations

  • Materials Available
  • Licensing
Date Published